Comparative safety and immunogenicity of an acellular versus whole-cell pertussis component of diphtheria-tetanus-pertussis vaccines in Senegalese infants.
A diphtheria and tetanus toxoid two-component acellular pertussis vaccine (DTaP), consisting of 25 micrograms glutaraldehyde-detoxified pertussis toxin (PT) and 25 micrograms native filamentous hemagglutinin (FHA), was compared with diphtheria and tetanus toxoid whole-cell pertussis vaccine (DTwP) in a randomized, double-blind manner in 286 Senegalese infants inoculated at two, four, and six months of age. In infants receiving DTaP a significantly lower rate of local reactions, crying and fever was observed than in infants receiving DTwP. One month after the third dose, the geometric mean titres for FHA antibodies were higher in the DTaP group, whereas increases in PT antibody titres were higher in the DTwP group. More than 90% of the infants had a fourfold or more increase in antibodies to both PT and FHA with either vaccine. Diphtheria, tetanus, and polio antibody responses were also measured and found to be comparable between the two groups. The results of this pilot study support the implementation of a field trial to compare the protective efficacy of these vaccines against pertussis in the same setting.
Simondon
F
F
Unité de Recherche sur les Maladies Infectieuses et Parasitaires, Institut Francais de Recherche Scientifique pour le Développement en Coopération (ORSTROM), Dakar, Senegal.
Yam
A
A
Gagnepain
J Y
JY
Wassilak
S
S
Danve
B
B
Cadoz
M
M
D000907:Antibodies, Bacterial / Q000032:analysis; D000914:Antibodies, Viral / Q000032:analysis; D001886:Bordetella pertussis / Q000276:immunology*; D003017:Clostridium tetani / Q000276:immunology; D004165:Diphtheria / Q000276:immunology* / Q000517:prevention & control*; D015721:Diphtheria-Tetanus-Pertussis Vaccine / Q000276:immunology*; D004311:Double-Blind Method; D005260:Female; D006388:Hemagglutinins / Q000276:immunology*; D006801:Humans; D007223:Infant; D008297:Male; D037342:Pertussis Toxin; D017955:Poliovirus / Q000276:immunology; D011054:Poliovirus Vaccine, Inactivated / Q000276:immunology; D012675:Senegal; D013742:Tetanus / Q000276:immunology* / Q000517:prevention & control*; D014611:Vaccination; D017778:Vaccines, Combined / Q000009:adverse effects / Q000276:immunology*; D014614:Vaccines, Synthetic / Q000009:adverse effects / Q000276:immunology*; D010566:Virulence Factors, Bordetella / Q000276:immunology*; D014917:Whooping Cough / Q000517:prevention & control*
D000907:Antibodies, Bacterial; D000914:Antibodies, Viral; D015721:Diphtheria-Tetanus-Pertussis Vaccine; D006388:Hemagglutinins; D011054:Poliovirus Vaccine, Inactivated; D017778:Vaccines, Combined; D014614:Vaccines, Synthetic; D010566:Virulence Factors, Bordetella; D037342:Pertussis Toxin